Intraoperative auricular acupuncture significantly reduces early postoperative pain and opioid consumption following total hip arthroplasty, improving recovery outcomes and increasing opioid-free hospital stays within ERAS protocols.
A large, real-world study presented at the AACE Annual Meeting found that adults with osteoporosis prescribed denosumab (Prolia) have no increased long-term risk of atypical femur fractures (AFF) compared to those using bisphosphonates.
Early transition from medium-dose inhaled corticosteroids to biologic therapy in asthma is associated with significantly greater reductions in exacerbations and systemic corticosteroid use compared with escalation to high-dose ICS, suggesting a potential shift in treatment strategy for patients with severe disease or type 2 inflammation.
The MOMENTUM study reveals that more than one-quarter of patients with resistant hypertension have underlying endogenous hypercortisolism. Often lacking classic phenotypic signs, this “lurking” endocrine driver highlights the critical need for routine biochemical screening and endocrinology referral in this high-risk population.
Topline results from the Phase 3 REVEAL-1 trial demonstrate that subcutaneous elegrobart achieved rapid, clinically meaningful reductions in proptosis and diplopia in active Thyroid Eye Disease patients with convenient Q4W or Q8W dosing.
Brepocitinib, a novel oral TYK2/JAK1 inhibitor, demonstrated significant clinical efficacy in the phase 3 VALOR trial for dermatomyositis, achieving superior improvement scores, higher remission rates and meaningful reductions in corticosteroid use compared with placebo. Rapid improvements in itch, muscle strength and quality of life were observed, with a favorable safety profile and no increase in major adverse events such as thrombosis or malignancy. These findings mark a major advancement in targeted therapy for this difficult-to-treat autoimmune disease.
Recent empirical studies reveal that unregulated celebrity and influencer alcohol promotions on social media routinely bypass age restrictions, exposing millions of underage users to subtle drinking cues. This digital marketing leverages parasocial relationships and perceived authenticity, significantly increasing young adults’ immediate intentions to consume alcohol and prompting calls for stricter algorithmic regulation.
A pre-specified subgroup analysis of the VESALIUS-CV trial demonstrates that the PCSK9 inhibitor evolocumab significantly reduces major adverse cardiovascular events and all-cause mortality in high-risk patients with diabetes who do not have established atherosclerosis, supporting earlier and more intensive lipid-lowering therapy.
A retrospective cohort study from UCLA reveals that the sustained use of medications for alcohol use disorder (MAUD) for three months or longer is associated with significantly improved 1-year and 3-year survival rates among patients with severe alcohol-related liver disease undergoing transplant evaluation.
Updated results from the phase 1/2 Beamion LUNG-1 study, presented at the European Lung Cancer Congress, show that the HER2-targeted therapy zongertinib achieved a 76% objective response rate and a median progression-free survival of 14.4 months as a first-line treatment for advanced HER2-mutant non-small cell lung cancer (NSCLC).